Following the signing of a landmark bill by US President Joe Biden, cannabis stocks received a boost on Friday as the bill expands marijuana research.
The bipartisan Medical Marijuana and Cannabinoid Research Expansion Act has made it easier for scientists to study this plant by streamlining the application process for approving cannabis-related scientific research and allowing researchers to grow or import marijuana for medical research purposes.
This directs the Department of Health and Human Services (DHHS) to investigate policies prohibiting research on marijuana and provide recommendations on how to eliminate these barriers. It also directs DHHS to research the therapeutic potential of marijuana.
This occurred after President Biden requested a review of the status of marijuana as a Schedule I substance under the Controlled Substances Act in October. It has been reported that the Secure and Fair Enforcement (SAFE) Banking Act will protect banks and other financial institutions from being penalized for providing services to legally-operating cannabis-related businesses, and may be passed by the end of the year.
On Monday morning, US cannabis stocks experienced a surge in response to news updates. Australis Capital Inc (CSE:AUSA, OTCQB:AUSAF) saw a rise of 15%, Planet 13 Holdings Inc (CSE:PLTH, OTCQX:PLNHF) increased by 5.6%, Jushi Holdings Inc (CSE:JUSH, OTCQX:JUSHF) rose by 6.8%, Delta 9 Cannabis Inc (TSX:DN) went up by 4.2%, and FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) saw a 2.8% rise.
The stocks of Valens Company (TSX:VLNS, OTCQX:VLNCF) Inc rose by 2%, Avikana Inc (TSX:AVCN, OTCQX:AVCNF) by 2.7%, Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) by 4%, and Nextleaf Solutions Ltd (CSE:OILS, OTCQB:OILFF) by 0.8%.
2FIRSTS will continue to track and report on this topic, with future updates available on the '2FIRSTSAPP'. Scan the QR code below to download the app.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
